Manufacturing, Packaging & Logistics In-Depth Focus 2021
Posted: 26 August 2021 | European Pharmaceutical Review | No comments yet
Features in this in-depth focus highlight some of the important developments in the cell and gene therapy market, as well as the key manufacturing strategies to consider when taking them from concept to commercialisation.
- UK at the forefront of advanced therapies
Advanced therapies are a ground-breaking new class of medicines that use gene therapy, cell therapy or tissue engineering to treat disease and injury. Rachel Bell, Trainee Patent Attorney at Marks & Clerk, and Ceri Roberts, Scientific Training Manager – Cellular and Molecular Therapies at NHS Blood and Transplant, discuss some important developments in the field and how the UK is playing a central role in realising their potential. - Taking cell and gene therapies from idea to commercialisation
David Vincent, Process Development Lead at eXmoor Pharma, details some of the critical steps that form the manufacturing strategy for providers of cell and gene therapies.
Issue
Related topics
Biologics, Drug Manufacturing, Gene therapy, Regenerative Medicine, Therapeutics
